Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392756 · ClinicalTrials.gov registry record · Phase 1
Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 624
- Enrollment target
NCT00392756: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00392756 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 624 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00392756, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 624 participants
- Enrollment target
Study Summary
The purpose of the study is to examine how Kallmann syndrome (KS) and idiopathic hypogonadotropic hypogonadism (IHH) affect reproductive hormones. These disorders are caused by a defect in Gonadotropin Releasing Hormone (GnRH) secretion. GnRH is a hormone released by a small gland in the brain called the hypothalamus. When GnRH is released, it signals another gland in the brain, the pituitary, to secrete the reproductive hormones that influence sex hormone (testosterone, estrogen) levels and gamete (sperm, egg cell) production. This study involves a detailed evaluation and 24-48 hours stay at the hospital. In this study, males and females ages 16 and older with IHH have a detailed evaluation which involves an overnight study at the hospital. Some men (18 years and older) may continue on to receive treatment with pulsatile GnRH. This treatment replaces the hormone which is absent in IHH and results in normalized testosterone and typically is effective in developing fertility.
Interventions
- DRUG gonadotropin releasing hormone (GnRH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 1989-04 |
| Est. Completion | 2019-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392756
The ClinicalTrials.gov registry entry for NCT00392756 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 624 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gonadotropin releasing hormone (GnRH) is the first listed.
NCT00392756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00392756 about?
NCT00392756 is a clinical study titled "Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)". The purpose of the study is to examine how Kallmann syndrome (KS) and idiopathic hypogonadotropic hypogonadism (IHH) affect reproductive hormones. These disorders are caused by a defect in Gonadotropin Releasing Hormone (GnRH) secretion. GnRH is a hormone released by a small gland in the brain calle...
What is the current status of trial NCT00392756?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 624 participants. The study started on 1989-04. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT00392756?
The interventions under investigation include: gonadotropin releasing hormone (GnRH) (DRUG).
Who is sponsoring clinical trial NCT00392756?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.